JP Morgan Chase
INFI

JP Morgan Chase’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

JP Morgan Chase’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,160
Closed -$244 – 7828
2023
Q2 		$244 Buy
1,160
+13
+1% +$2 ﹤0.01% 6616
2023
Q1 		$0 Sell
1,147
-1,523
-57% -$676 ﹤0.01% 7409
2022
Q4 		$2K Sell
2,670
-2,295
-46% -$1.95K ﹤0.01% 6362
2022
Q3 		$6K Buy
4,965
+1,135
+30% +$1.22K ﹤0.01% 6074
2022
Q2 		$2K Sell
3,830
-47,795
-93% -$36.7K ﹤0.01% 6321
2022
Q1 		$59K Buy
51,625
+11,398
+28% +$13.6K ﹤0.01% 5732
2021
Q4 		$91K Buy
40,227
+7,847
+24% +$19.7K ﹤0.01% 5727
2021
Q3 		$110K Sell
32,380
-1,226
-4% -$3.78K ﹤0.01% 5522
2021
Q2 		$100K Buy
33,606
+33,550
+59,911% +$106K ﹤0.01% 5544
2021
Q1 		$0 Sell
56
-41,225
-100% -$138K ﹤0.01% 6461
2020
Q4 		$88K Buy
41,281
+41,256
+165,024% +$68K ﹤0.01% 5029
2020
Q3 		$0 Hold
25
– – ﹤0.01% 5883
2020
Q2 		$0 Buy
25
+24
+2,400% +$23 ﹤0.01% 5798
2020
Q1 		$0 Hold
1
– – ﹤0.01% 5843
2019
Q4 		$0 Hold
1
– – ﹤0.01% 5963
2019
Q3 		$0 Sell
1
-219,054
-100% -$299K ﹤0.01% 6033
2019
Q2 		$381K Sell
219,055
-209,534
-49% -$337K ﹤0.01% 4358
2019
Q1 		$806K Sell
428,589
-16,596
-4% -$24.3K ﹤0.01% 3928
2018
Q4 		$525K Buy
+445,185
New +$801K ﹤0.01% 4108
2017
Q4 		– Sell
-118,435
Closed -$135K – 5626
2017
Q3 		$135K Buy
+118,435
New +$147K ﹤0.01% 4222
2017
Q2 		– Sell
-226,101
Closed -$730K – 5303
2017
Q1 		$730K Sell
226,101
-3,044
-1% -$7.49K ﹤0.01% 3546
2016
Q4 		$309K Sell
229,145
-4,755
-2% -$6.21K ﹤0.01% 3985
2016
Q3 		$365K Sell
233,900
-228,300
-49% -$351K ﹤0.01% 3508
2016
Q2 		$614K Sell
462,200
-29,850
-6% -$140K ﹤0.01% 3359
2016
Q1 		$2.59M Sell
492,050
-9,075
-2% -$55.5K ﹤0.01% 2569
2015
Q4 		$3.93M Sell
501,125
-71,050
-12% -$612K ﹤0.01% 2366
2015
Q3 		$4.83M Buy
572,175
+2,243
+0.4% +$20.7K ﹤0.01% 2244
2015
Q2 		$6.24M Buy
569,932
+130,230
+30% +$1.67M ﹤0.01% 2260
2015
Q1 		$6.15M Buy
439,702
+297,799
+210% +$4.55M ﹤0.01% 2209
2014
Q4 		$2.4M Buy
+141,903
New +$2.07M ﹤0.01% 2864
2014
Q2 		– Sell
-177,848
Closed -$2.12M – 3647
2014
Q1 		$2.12M Buy
177,848
+19,047
+12% +$256K ﹤0.01% 2528
2013
Q4 		$2.19M Sell
158,801
-18,788
-11% -$265K ﹤0.01% 2692
2013
Q3 		$3.1M Sell
177,589
-22,246
-11% -$426K ﹤0.01% 2508
2013
Q2 		$3.24M Buy
+199,835
New +$6.18M ﹤0.01% 2441

Other funds holding INFI

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

JP Morgan Chase's INFI Position: Q3 2023 in Review

JP Morgan Chase sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2023, closing a stake of 1,160 shares — an estimated $244 sold.

JP Morgan Chase first reported a position in INFI in Q2 2013 and held it in 34 quarters. The position peaked at $6.24M in Q2 2015. 3 funds tracked by Wall St. Rank hold INFI as of Q3 2023.

  • JP Morgan Chase reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • JP Morgan Chase sold 1,160 Infinity Pharmaceuticals, Inc. shares in Q3 2023, an estimated $244.
  • JP Morgan Chase first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 34 quarters.
  • JP Morgan Chase's Infinity Pharmaceuticals, Inc. position peaked at $6.24M in Q2 2015.
  • 3 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2023.

Based on JP Morgan Chase's 13F filing for Q3 2023, filed 14 Nov 2023.